SIREN : 804573434
BIOPLAN EUROPE is a French company founded 11 years ago, specialized in the sector Activités des sièges sociaux. Based in VAL-DE-REUIL (27100), this company of category ETI shows in 2024 a revenue of 6.8 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-04-18
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 6 786 367 € | 7 199 966 € | 5 929 998 € |
| Net income | 21 014 155 € | 5 604 859 € | -1 475 927 € |
| EBITDA | 1 085 623 € | 822 524 € | 1 039 170 € |
| Net margin | 309.7% | 77.8% | -24.9% |
In 2024, BIOPLAN EUROPE achieves revenue of 6.8 M€. Over the period 2022-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +7.0%. Slight decline of -6% vs 2023. After deducting consumption (0 €), gross margin stands at 6.8 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 1.1 M€, representing 16.0% of revenue. Positive scissor effect: EBITDA margin improves by +4.6 pts, sign of improved operational efficiency. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 21.0 M€, i.e. 309.7% of revenue. This profit can be retained or distributed to shareholders.
6 786 367 €
6 786 367 €
1 085 623 €
-3 898 572 €
21 014 155 €
16.0%
The debt ratio (= Financial debt / Equity x 100) stands at 278%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 20%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 3.0 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 318.2% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
277.946%
19.699%
318.244%
2.952
In 2024, the debt ratio of BIOPLAN EUROPE (277.95) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of BIOPLAN EUROPE (19.7%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of BIOPLAN EUROPE (2.95) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 290.33. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 482.6x. Operating income very largely covers interest expenses: high safety margin.
290.328
482.642
In 2024, the liquidity ratio of BIOPLAN EUROPE (290.33) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of BIOPLAN EUROPE (482.6x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 19 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 204 days. Excellent situation: suppliers finance 185 days of the operating cycle (retail model). Overall, WCR represents 2503 days of revenue, i.e. 47.2 M€ to permanently finance. Over 2022-2024, WCR increased by +848%, requiring additional financing.
47 193 414 €
19 j
204 j
0 j
2503 j
Based on 103 transactions of similar company sales in 2024, the value of BIOPLAN EUROPE is estimated at 43 460 029 € (range 14 557 420€ - 113 670 948€). With an EBITDA of 1 085 623€, the sector multiple of 5.0x is applied. The price/revenue ratio is 0.38x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 103 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare BIOPLAN EUROPE with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sièges sociaux
The revenue of BIOPLAN EUROPE in 2024 is 6.8 M€.
Yes, BIOPLAN EUROPE generated a net profit of 21.0 M€ in 2024.
The headquarters of BIOPLAN EUROPE is located in VAL-DE-REUIL (27100), in the department Eure.
The tax return of BIOPLAN EUROPE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
BIOPLAN EUROPE operates in the sector Activités des sièges sociaux (NAF code 70.10Z). See the 'Sector positioning' section above to compare the company with its competitors.